← back to search
Esther Welkowsky
Intarcia Therapeutics (United States) ·
Area of research
Oncology · Immunology
Research interest
Research interests include Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, and Pancreatic and Hepatic Oncology Research.
h-index
6
citations
368
works
13
NIH funding
—
primary concept
Medicine
email
✉ Find email ↗
Recent publications
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results
Nature Medicine
2025
cited by
37
position: middle
doi
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
Nature Medicine
2024
cited by
229
position: middle
doi
Grants
No grants ingested yet.
Frequent collaborators
Zev A. Wainberg
· UCLA Medical Center
2
papers (2024–2025)
Vincent Chung
· City Of Hope National Medical Center
2
papers (2024–2025)
Colin D. Weekes
· Harvard University
2
papers (2024–2025)
Alexis D. Leal
· NYU Langone Health
2
papers (2024–2025)
Peter C. DeMuth
· Melrose-Wakefield Hospital
2
papers (2024–2025)
Thian Kheoh
· Mirati Therapeutics (United States)
2
papers (2024–2025)
Craig Devoe
· Northwell Health
2
papers (2024–2025)
Eileen M. O’Reilly
· Erasmus MC Cancer Institute
2
papers (2024–2025)
Pashtoon Murtaza Kasi
· Cornell University
2
papers (2024–2025)
Muhammad Furqan
· University of Edinburgh
2
papers (2024–2025)
Shubham Pant
· The University of Texas MD Anderson Cancer Center
2
papers (2024–2025)
James Perry
· University of Arkansas for Medical Sciences
2
papers (2024–2025)
Lisa K. McNeil
· University of Liverpool
2
papers (2024–2025)
Lochana M. Seenappa
· Io Therapeutics (United States)
1
papers (2024–2024)
Olca Baştürk
· Cornell University
1
papers (2024–2024)
Haley VanWyk
· Intarcia Therapeutics (United States)
1
papers (2024–2024)
Christopher M. Haqq
· Intarcia Therapeutics (United States)
1
papers (2024–2024)
Amy Tavares
· Intarcia Therapeutics (United States)
1
papers (2024–2024)
—
·
1
papers (2025–2025)